ClinicalTrials.Veeva

Menu

Circulating Tumoral DNA in Choroidal Melanoma (ctDNA MU)

I

Institut Curie

Status

Completed

Conditions

Choroidal Melanoma

Treatments

Biological: Blood sampling

Study type

Interventional

Funder types

Other

Identifiers

NCT02875652
IC 2012-08

Details and patient eligibility

About

Quantification and follow-up during 3 years of circulating tumoral DNA in patients with choroidal melanoma

Full description

This study is a prospective, open-labelled, monocentric trial. The aim is to observe, in patient with choroidal melanoma (any stage of the disease), the prevalence of the circulating tumor DNA at the diagnostic and its evolution during 3 years.

The patient will have a blood sample at the following times :

  • T0: before treatment of the primary tumor.
  • T1: 1 months after the end of the local treatment.
  • T2: at 7 months.
  • Tn: every 6 months up to 3 years.

Enrollment

800 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Aged 18 years old or more.
  • Patient with a recent choroidal melanoma before the start of the specific treatment.
  • Patient able to stand a blood collection.
  • Work-up for extension (CT).
  • Patient explanation given and consent information signed or by legal representative

Exclusion criteria

  • Patient without social protection / insurance.
  • Person deprived of liberty or under guardianship.
  • Inability to submit to medical monitoring of the trial for reasons of geography, social or psychological

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

800 participants in 1 patient group

Blood sampling
Experimental group
Treatment:
Biological: Blood sampling

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems